Introduction to Rule 83
Rule 83 of the Securities and Exchange Commission (SEC) allows companies to request confidential treatment for certain information submitted in their filings. This provision is essential for protecting sensitive business information that could potentially harm a company's competitive position if disclosed publicly.
The SEC reviews each confidential treatment request (CTR) to determine whether the information in question meets the requirements for confidentiality. Companies must demonstrate that the information is both confidential and sensitive, and that its disclosure would cause substantial competitive harm.
Eligibility for Confidential Treatment
Not all information submitted to the SEC is eligible for confidential treatment. To qualify, the information must be both confidential and sensitive, such as trade secrets, proprietary business methods, or other competitive sensitive information. Companies must also demonstrate that the information is not otherwise publicly available.
The SEC has established specific procedures for submitting CTRs, including the requirement to submit a formal request and to identify the specific information for which confidentiality is sought. Companies must also provide a detailed explanation of why the information is confidential and sensitive.
Procedure for Submitting Confidential Treatment Requests
To submit a CTR, companies must follow the procedures outlined in Rule 83. This includes submitting a formal request to the SEC, along with the required documentation and explanations. The request must be signed by an authorized representative of the company and must include a detailed description of the information for which confidentiality is sought.
The SEC reviews each CTR to determine whether the information meets the requirements for confidentiality. If the request is approved, the SEC will grant confidential treatment for the specified period, which is typically up to five years. Companies must then resubmit their request if they wish to extend the confidentiality period.
Consequences of Non-Compliance
Failure to comply with the requirements of Rule 83 can result in serious consequences, including the denial of confidential treatment and the public disclosure of sensitive information. Companies that submit false or misleading information in their CTRs may also face enforcement action by the SEC.
To avoid these risks, companies must ensure that they fully understand the requirements of Rule 83 and that they comply with all applicable procedures and deadlines. This may involve seeking the advice of experienced securities lawyers or other professionals who are familiar with the SEC's rules and procedures.
Best Practices for Confidential Treatment Requests
To increase the likelihood of a successful CTR, companies should carefully review the SEC's rules and procedures and ensure that they submit complete and accurate information. They should also provide detailed explanations of why the information is confidential and sensitive, and demonstrate that the information is not otherwise publicly available.
Companies should also be prepared to respond to any questions or concerns raised by the SEC during the review process. This may involve providing additional information or explanations, or addressing any issues or deficiencies identified by the SEC. By following these best practices, companies can help ensure that their CTRs are successful and that their sensitive information is protected.
Frequently Asked Questions
What is the purpose of Rule 83 confidential treatment requests?
The purpose of Rule 83 is to allow companies to protect sensitive information from public disclosure, while still complying with the SEC's filing requirements.
What types of information are eligible for confidential treatment?
Eligible information includes trade secrets, proprietary business methods, and other competitive sensitive information that is not otherwise publicly available.
How do I submit a confidential treatment request to the SEC?
To submit a CTR, companies must follow the procedures outlined in Rule 83, including submitting a formal request and providing the required documentation and explanations.
What are the consequences of non-compliance with Rule 83?
Non-compliance can result in the denial of confidential treatment, public disclosure of sensitive information, and enforcement action by the SEC.
How long does confidential treatment last?
Confidential treatment typically lasts for up to five years, although companies may resubmit their request to extend the confidentiality period.
Do I need to hire a lawyer to submit a confidential treatment request?
While not required, it is highly recommended that companies seek the advice of experienced securities lawyers or other professionals to ensure compliance with the SEC's rules and procedures.